Randomized, controlled trial of clonidine for smoking cessation in a primary care setting

Peter Franks, J. Harp, B. Bell

Research output: Contribution to journalArticle

42 Scopus citations

Abstract

Clonidine hydrochloride has been reported to reduce tobacco withdrawal symptoms and facilitate smoking cessation. We enrolled 185 subjects, 92 receiving clonidine and 93 receiving placebo, in a randomized, double-blind study of clonidine for smoking cessation in a primary care setting. Clonidine had no demonstrable effect on withdrawal (8 of 11 measures favoring placebo). At 4 weeks, 17 (18%) subjects receiving clonidine had quit compared with 13 (14%) receiving placebo (χ2 = 0.7; 90% confidence interval of benefit from clonidine, -4% to 13%). At 4 weeks, the mean number of cigarettes smoked was 17.7 for those receiving clonidine and 17.5 for those receiving placebo (t = 0.1; 90% confidence interval of benefit from clonidine, -4.1 to 3.7 cigarettes per day). These results provide little support for a beneficial effect of clonidine on tobacco withdrawal symptoms, quitting, or smoking reduction in a primary care setting.

Original languageEnglish (US)
Pages (from-to)3011-3013
Number of pages3
JournalJournal of the American Medical Association
Volume262
Issue number21
DOIs
StatePublished - 1989
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Randomized, controlled trial of clonidine for smoking cessation in a primary care setting'. Together they form a unique fingerprint.

  • Cite this